Actively Recruiting
Phase 2 Randomized Study of Futibatinib 16 mg and 20 mg Oral Tablets in Patients With Advanced Cholangiocarcinoma With FGFR2 Gene Fusions or Rearrangements
Led by Taiho Oncology, Inc. · Updated on 2026-09-01
120
Participants Needed
65
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating futibatinib, an oral FGFR inhibitor, in patients with advanced cholangiocarcinoma CCA that have FGFR2 gene fusions or rearrangements. This multinational Phase 2 study aims to confirm the clinical benefit of a 20 mg dose and assess the safety and effectiveness of a 16 mg dose in patients who have previously received treatment for their CCA. Participants are randomly assigned to one of two groups one receiving 16 mg of futibatinib daily and the other receiving 20 mg daily. Both treatments are taken orally every day in 21-day cycles. Patients may continue receiving the medication until their disease progresses or other withdrawal criteria are met. During the study, participants undergo assessments including imaging to measure tumor response, safety monitoring for side effects, and quality of life evaluations. Researchers will evaluate outcomes such as the objective response rate, duration of response, progression-free survival, overall survival, and adverse events up to 12 months after the study ends. The total participation duration depends on individual treatment response and disease progression.
CONDITIONS
Brief Title
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Research Team
T
Taiho Oncology, INC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here